WHO Therapeutics landscape analysis for COVID-19
All the medicines, including both repurposed and new compounds, which may be of potential interest for the treatment of COVID-19 are included in this analysis. As of 14 April 2020, the application contains 133 therapeutics. Users can select between repurposed medicines and new compounds by type or mechanism of action, such as protease inhibitors, nucleotide analogues, immunomodulators and mAbs. They can also analyse and evaluate the best evidence available for COVID-19 and other diseases, covering in vitro, in vivo, and clinical trials.